NVO Profile
Novo Nordisk A/S, a global healthcare company founded in 1923 and headquartered in Bagsvaerd, Denmark, specializes in the research, development, manufacture, and marketing of pharmaceutical products. The company operates through two primary segments: Diabetes and Obesity Care, and Biopharm, addressing a wide range of chronic health conditions and rare diseases.
The Diabetes and Obesity Care segment offers an extensive portfolio that includes insulins, GLP-1 receptor agonists, related delivery systems, oral antidiabetic products, and treatments for obesity and other chronic diseases. This segment focuses on providing innovative solutions to manage and treat diabetes and obesity, which are among the most prevalent health issues globally.
In the Biopharmaceuticals segment, Novo Nordisk provides products for haemophilia, growth disorders, and hormone replacement therapy. This segment is dedicated to developing therapies for rare and severe chronic conditions, enhancing the quality of life for patients with limited treatment options. The company's collaboration agreements, such as with Gilead Sciences, Inc., expand its reach and capabilities in addressing complex health challenges.
Additionally, Novo Nordisk engages in research collaborations to advance its pharmaceutical innovations. Notably, it has a research partnership with Lumen Bioscience, Inc. to explore new strategies for delivering oral biologics aimed at treating cardiometabolic diseases. Through these strategic initiatives and its comprehensive product offerings, Novo Nordisk continues to be a leader in the global healthcare industry, committed to improving patient outcomes and advancing medical science.
|
